The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity
Open accessAbstract
Quinolones are broad-spectrum synthetic antibacterial drugs first obtained during the synthesis of chloroquine. Nalidixic acid, the prototype of quinolones, first became available for clinical consumption in 1962 and was used mainly for urinary tract infections caused by Escherichia coli and other pathogenic Gram-negative bacteria. Recently, significant work has been carried out to synthesize novel quinolone analogues with enhanced activity and potential usage for the treatment of different bacterial diseases. These novel analogues are made by substitution at different sites—the variation at the C-6 and C-8 positions gives more effective drugs. Substitution of a fluorine atom at the C-6 position produces fluroquinolones, which account for a large proportion of the quinolones in clinical use. Among others, substitution of piperazine or methylpiperazine, pyrrolidinyl and piperidinyl rings also yields effective analogues. A total of twenty six analogues are reported in this review. The targets of quinolones are two bacterial enzymes of the class II topoisomerase family, namely gyrase and topoisomerase IV. Quinolones increase the concentration of drug-enzyme-DNA cleavage complexes and convert them into cellular toxins; as a result they are bactericidal. High bioavailability, relative low toxicity and favorable pharmacokinetics have resulted in the clinical success of fluoroquinolones and quinolones. Due to these superior properties, quinolones have been extensively utilized and this increased usage has resulted in some quinolone-resistant bacterial strains. Bacteria become resistant to quinolones by three mechanisms: (1) mutation in the target site (gyrase and/or topoisomerase IV) of quinolones; (2) plasmid-mediated resistance; and (3) chromosome-mediated quinolone resistance. In plasmid-mediated resistance, the efflux of quinolones is increased along with a decrease in the interaction of the drug with gyrase (topoisomerase IV). In the case of chromosome-mediated quinolone resistance, there is a decrease in the influx of the drug into the cell.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Plasmid-mediated quinolone resistance: an update
Rodríguez-Martínez, J. M., Velasco, C., Pascual, Á., Cano, M. E., Martínez-Martínez, L., Martínez-Martínez, L., & Pascual, Á. (2011) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-010-0120-2 · Cited by 306
Cited by
Important Flavonoids and Their Role as a Therapeutic Agent
Ullah, A., Munir, S., Badshah, S. L., Khan, N., Ghani, L., Poulson, B. G., Emwas, A.-H., & Jaremko, M. (2020) · Molecules · doi:10.3390/molecules25225243 · Cited by 1,696
Self-citationKlebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance
Navon-Venezia, S., Kondratyeva, K., & Carattoli, A. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux013 · Cited by 1,286
The Characteristic of Virulence, Biofilm and Antibiotic Resistance of Klebsiella pneumoniae
Wang, G., Zhao, G., Chao, X., Xie, L., & Wang, H. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17176278 · Cited by 591
Metadata
- Authors
- Naeem, A., Badshah, S., Muska, M., Ahmad, N., & Khan, K.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2016-03-28
- Volume
- 21
- Issue
- 4
- Pages
- 268
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2305253637
- Cited by
- 218
- References
- 1
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.